Washington University SPORE in Pancreatic Cancer

华盛顿大学 SPORE 在胰腺癌中的应用

• 批准号: 10708572
• 负责人: David G DeNardo
• 金额: $ 206.5万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-28 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708572
• 关键词: Agonist; Basic Science; Bioinformatics; Biometry; California; Cancer Biology; Cancer Center; Cancer Research Project; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communities; Development; Diagnosis; Disease; Drug resistance; Ensure; Environment; Ethics; Faculty; Fostering; Funding; Genomics; Goals; ITGAM gene; Image; Immunologics; Immunology; Immunotherapeutic agent; Immunotherapy; Individual; Infrastructure; Institution; Leadership; Malignant Neoplasms; Malignant neoplasm of pancreas; Mentors; Metabolic; Minority; Mission; Nebraska; North Carolina; Pancreatic Ductal Adenocarcinoma; Patient Participation; Patient-Focused Outcomes; Patients; Pennsylvania; Quality of life; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Specialized Program of Research Excellence; Stress; Testing; Therapeutic Clinical Trial; Therapeutic Trials; Training; Translational Research; Translations; Universities; Washington; bench-to-bedside translation; cancer genomics; cancer type; career; clinical care; clinical practice; design; drug development; gastrointestinal; immune resistance; improved; improved outcome; innovation; inter-institutional; leukemia; medical schools; multidisciplinary; neoantigen vaccine; novel; novel diagnostics; novel strategies; novel therapeutic intervention; patient population; programs; recruit; resistance mechanism; translational applications; translational cancer research; translational impact; translational potential; treatment strategy

PROJECT SUMMARY The Washington University Specialized Program of Research Excellence (SPORE) in Pancreatic Cancer is a highly translational cancer research program focused entirely on the deadliest form of the disease, pancreatic ductal adenocarcinoma (PDAC). Our outstanding investigators have complementary expertise in basic and clinical studies, and our teams leverage individual expertise in immunology, cancer biology, drug development, genomics, and clinical care to develop novel diagnostic and therapeutic approaches for PDAC. This SPORE application includes three research projects, an administrative core (Core A), two shared- resource cores [Biospecimen Core (Core B) and Biostatistics and Bioinformatics Core (Core C)], and developmental research (DRP) and career enhancement (CEP) programs. In collaboration with our External (EAB) and Internal (IAB) Advisory Boards, we intentionally selected projects with the greatest potential to impact the outcome for patients with PDAC. Basic research at WUSM and UPenn has led to the development of the following three research projects, all of which feature innovative investigator-initiated therapeutic trials for PDAC. All projects deemed to have the most potential for translational impact and share an immunologic theme in their approach. This immunologic theme leverages institutional strengths and highlights our team’s expertise and leadership in this field. Thus far, the immunologic and metabolic therapies that have been increasingly successful for controlling other cancer types have not been impactful in PDAC. Our project leaders have made noteworthy contributions to elucidate the mechanisms underlying this immunologic resistance and drug resistance in PDAC and developed several exciting strategies with potential to overcome these obstacles. The three projects in this application are designed to have significant potential to change clinical practice within 5 years. Project 1. Employing CD11b-agonists to render PDAC responsive to immunotherapy Project 2. Mechanisms of Resistance to Neoantigen Vaccines in PDAC Project 3. Targeting Stress-induced MK2 as Novel Strategy in Pancreatic Cancer Our long-term goals are to improve the survival and the quality of life of patients diagnosed with PDAC. To achieve this goal, we will promote institutional and inter-institutional collaborative research, with an emphasis on translation. We anticipate that no singular approach will solve PDAC and fully commit to supporting the development of novel research concepts as well as highly promising young investigators. Our SPORE will provide access to pancreatic cancer–specific resources to facilitate this mission.

项目概要 华盛顿大学胰腺癌专业卓越研究计划 (SPORE) 是一个 高度转化的癌症研究计划完全专注于最致命的疾病——胰腺癌 我们杰出的研究人员在基础和导管腺癌 (PDAC) 方面拥有互补的专业知识。 临床研究，我们的团队利用免疫学、癌症生物学、药物开发等方面的个人专业知识， 基因组学和临床护理开发新的 PDAC 诊断和治疗方法。 该 SPORE 应用程序包括三个研究项目、一个管理核心（核心 A）、两个共享项目 资源核心[生物样本核心（核心 B）和生物统计和生物信息学核心（核心 C）]，以及 与我们的外部合作开展发展研究 (DRP) 和职业提升 (CEP) 计划。 (EAB) 和内部 (IAB) 顾问委员会，我们有意选择最具影响潜力的项目 WUSM 和 UPenn 的基础研究促进了 PDAC 患者的治疗结果。 以下三个研究项目均以研究者发起的 PDAC 创新治疗试验为特色。 所有被认为最具转化影响潜力并在其研究中共享免疫学主题的项目 该免疫学主题利用了机构优势并突出了我们团队的专业知识和能力。 迄今为止，免疫学和代谢疗法在该领域处于领先地位。 控制其他癌症类型对 PDAC 没有产生影响。 对阐明 PDAC 免疫抵抗和耐药机制的贡献 并制定了一些令人兴奋的策略，有可能克服这些障碍。这三个项目。 应用程序的设计具有在 5 年内改变临床实践的巨大潜力。 项目 1. 使用 CD11b 激动剂使 PDAC 对免疫疗法产生反应 项目2. PDAC新抗原疫苗耐药机制 项目 3. 将压力诱导的 MK2 作为治疗胰腺癌的新策略 我们的长期目标是提高 PDAC 患者的生存率和生活质量。 为实现这一目标，我们将促进机构和机构间的合作研究，重点是 我们预计没有单一方法可以解决 PDAC 问题，并全力支持 我们的 SPORE 将开发新颖的研究概念以及极具前途的年轻研究人员。 提供获取胰腺癌特定资源的途径，以促进这一使命。